#AACR21 Interested in methods that can improve responses to #AdoptiveCellTherapy? This @CIR_AACR spotlighted article covers just that! #CIRSpotlight #AntigenHeterogeneity #AntigenSpreading https://t.co/K0eEmkdLix
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/gtiWVhkh9l #VersitiResearch https://t.co/K28IDgEWCq
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/2G1G4B0QvJ #VersitiResearch https://t.co/DdcckZQMNr
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/yCozVnqpgx #VersitiResearch https://t.co/fShFBahi8M
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/7Xh4LOF3sY #VersitiResearch https://t.co/bDxVzGuQ0Z
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/qI92ABABqZ #VersitiResearch https://t.co/qctEQVSQ1b
Versiti Investigator Weiguo Cui, MD, PhD, was published in @CIR_AACR for his work to identify additional #cancer tumor-associated antigens that can be targeted for treatment. Learn more: https://t.co/43MMTMSENS #VersitiResearch https://t.co/maxyGGQid3
RT @CancerResearch: CRI Fellow Ryan Zander, Ph.D., of @BloodCenterWI is the co-author of a new paper in Cancer Immunology Research, which d…
CRI Fellow Ryan Zander, Ph.D., of @BloodCenterWI is the co-author of a new paper in Cancer Immunology Research, which discusses the importance of generating cross presentation with the use of cell therapy in solid tumors. https://t.co/pj3ZI5VDwn
RT @CIR_AACR: Interested in how you can overcome #AntigenHeterogeneity and #AntigenSpreading to improve efficacy of #AdoptiveCellTherapy? C…
RT @CIR_AACR: Interested in how you can overcome #AntigenHeterogeneity and #AntigenSpreading to improve efficacy of #AdoptiveCellTherapy? C…
RT @CIR_AACR: Interested in how you can overcome #AntigenHeterogeneity and #AntigenSpreading to improve efficacy of #AdoptiveCellTherapy? C…
Interested in how you can overcome #AntigenHeterogeneity and #AntigenSpreading to improve efficacy of #AdoptiveCellTherapy? Check this article out now! @wcui4 @GangXin1 #ReACT #DC1 https://t.co/rz9ZWY2Qmj https://t.co/0eCRzUSDzw